Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assisted Cantargia in entering into a R&D agreement with Panorama Research
Mandate

Vinge assisted Cantargia in entering into a R&D agreement with Panorama Research

August 24, 2017

Cantargia AB (“Cantargia”) of Lund, Sweden, and Panorama Research Inc. (“Panorama”), a California based specialist antibody developer, have entered into a collaboration agreement to jointly accelerate Cantargia's second program directed towards autoimmune and inflammatory diseases. 

Cantargia’s proprietary antibodies, against the molecular target IL1RAP, will be affinity matured and humanized using Panorama’s proprietary technology. In addition, Panorama will generate cell lines optimized for high level GMP production. Cantargia will be responsible for subsequent down-stream development. Under the terms of the agreement, Panorama will share risk in the project in exchange for a fraction of future incomes from third parties or future sales.
 
Kristoffer Franzkeit advised Cantargia.

Related

Vinge has advised Boliden in connection with a directed share issue of SEK 3.75 billion

 Vinge has advised Boliden AB in connection with a directed share issue through which the company raises proceeds of approximately SEK 3.75 billion before transaction costs.
March 21, 2025

Vinge advises EQT on its EUR 890 million sale of Dellner Couplers to Wabtec

 Vinge together with Milbank advises the EQT VIII fund (“EQT”) on its sale of Dellner Couplers (“Dellner”), a leading provider of train connection systems for passenger rail, to Wabtec Corporation (a fortune 500 company listed on the New York Stock Exchange, NYSE: WAB). The transaction values Dellner at approximately EUR 890 million. The transaction is subject to customary conditions and regulatory approvals.
March 19, 2025

Vinge advises Ambea on the acquisition of Validia

 Vinge has acted as advisor to Ambea AB (publ) together with the Finnish law firm Krogerus in connection with the acquisition of Validia Oy from Invalidiliitto, the Finnish Association for the Disabled, a leading care provider in Finland. Through the acquisition, Ambea establishes a presence in the Finnish market and strengthens its position as the only care provider with operations in the four largest Nordic countries. The purchase price amounts to a total of SEK 1, 382 million.
March 12, 2025